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Abstract
Accumulating evidence shows a key function for astrocytic connexin43 (Cx43) signaling in epi-
lepsy. However, the lack of experimental distinction between Cx43 gap junction channels (GJCs)
and hemichannels (HCs) has impeded the identification of the exact contribution of either channel
configurations to epilepsy. We therefore investigated whether TAT-Gap19, a Cx mimetic peptide
that inhibits Cx43 HCs but not the corresponding Cx43 GJCs, influences experimentally induced
seizures in rodents. Dye uptake experiments in acute hippocampal slices of mice demonstrated
that astroglial Cx43 HCs open in response to the chemoconvulsant pilocarpine and this was inhib-
ited by TAT-Gap19. In vivo, pilocarpine-induced seizures as well as the accompanying increase in
D-serine microdialysate levels were suppressed by Cx43 HC inhibition. Moreover, the anticonvul-
sant action of TAT-Gap19 was reversed by exogenous D-serine administration, suggesting that
Cx43 HC inhibition protects against seizures by lowering extracellular D-serine levels. The anticon-
vulsive properties of Cx43 HC inhibition were further confirmed in electrical seizure mouse
models, i.e. an acute 6 Hertz (Hz) model of refractory seizures and a chronic 6 Hz corneal kindling
model. Collectively, these results indicate that Cx43 HCs play a role in seizures and underscore
their potential as a novel and druggable target in epilepsy treatment.
K E YWORD S
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Abbreviations: []e, extracellular ion concentration; []i, intracellular ion concentration; aCSF, artificial cerebrospinal fluid; AP, anterior-posterior; ASDs, anti-seizure
drugs; ATP, adenosine triphosphate; CBX, carbenoxolone; CL, cytoplasmic loop; CT, carboxy-terminal tail; Ctr, control condition; Cx(s)(43), connexin(s)(43); DAAO,
D-amino acid oxidase; DV, dorso-ventral; eGFP, enhanced green fluorescent protein; ECoG, electrocorticograph(y/ic); EtBr, ethidium bromide; ETSP, Epilepsy
Therapy Screening Program; GFAP, glial fibrillary acidic protein; GABA, gamma-aminobutyric acid; GJC(s), gap junction channel(s); GJCC, gap junction channel
coupling; HC(s), hemichannel(s); HPLC, high-performance liquid chromatography; Hz, Hertz; i.c.v., intracerebroventricular(ly); i.p., intraperitoneal(ly); ML, medial-
lateral; NIH, National Institutes of Health; NINDS, National Institute of Neurological Disorders and Stroke; NMDA, N-methyl-D-aspartate; PBS, phosphate
buffered saline; RT, room temperature; s.c., subcutaneous(ly); scrTG19, scrambled TAT-Gap19; SEM, standard error of the mean; SSS, seizure severity score; TAT,
transactivator of transcription; TG19, TAT-Gap19; TSSS, total seizure severity score; P40, 40 min pilocarpine incubation; WMS, Wilcoxon matched-pairs signed-
rank.
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1 | INTRODUCTION
Despite the large number of marketed anti-seizure drugs (ASDs), one
third of patients with epilepsy suffer from intolerable side effects and/
or drug resistance (Kwan, Schachter, & Brodie, 2011). Pharmacoresist-
ance to several ASDs can be explained by the similar mechanisms of
action, which are mainly targeting neuronal mechanisms (Janigro &
Walker, 2014). The discovery of ASDs with distinct activity profiles
(e.g., targeting non-neuronal elements) has therefore become an impor-
tant new avenue for the development of epilepsy treatments (Baulac &
Pitkänen, 2008). In line with this notion, the present study evaluates
the potential of astroglial connexin (Cx) hemichannels (HCs) as novel
druggable targets for epilepsy. Astrocytes express Cx43 and Cx30;
here we focus on Cx43 as the major astrocytic Cx (Orellana, Retamal,
Moraga-Amaro, & Stehberg, 2016).
Cx43 proteins are building blocks of two different channel types in
astrocytes (Nagy & Rash, 2000; Naus, Bechberger, Caveney, & Wilson,
1991; Orellana et al., 2016). While Cx43 gap junction channels (GJCs)
connect two adjacent astrocytes, Cx43 HCs are located between the
cytosol of a single astrocyte and the extracellular environment (Abu-
dara et al., 2014). When open, Cx43 HCs form a high conductance
pathway (single channel conductance of 220 pS) allowing the passage
of molecules and ions below 1.5 kDa (Wang et al., 2012). Some con-
troversies regarding the functional characteristics of Cx43 HCs are
described (reviewed in Nielsen, Hansen, Ransom, Nielsen, & MacAulay,
2017), however, several research papers demonstrate that, if opening
is limited in nature, glial Cx43 HCs may provide a pathway for con-
trolled release of various neuroactive substances, called gliotransmit-
ters (e.g., glutamate and adenosine triphosphate (ATP) release; Orellana
et al., 2011; Ye, Wyeth, Baltan-Tekkok, & Ransom, 2003) or the entry
of major signaling ions like Ca21. The latter will transiently increase the
intracellular Ca21 concentration ([Ca21]i), which can affect a variety of
physiological cell functions (e.g., regulation of cell volume and synaptic
activity; Chever, Lee, & Rouach, 2014; Chever, Pannasch, Ezan, &
Rouach, 2014; Lohman & Isakson, 2014; Meunier et al., 2017; Giaume,
Leybaert, Naus, & Saez, 2013; Orellana et al., 2016; Pannasch &
Rouach, 2013; Torres et al., 2012; Walrave et al., 2016).
Sustained Cx43 HC opening on the other hand could release
excessive amounts of chemically active molecules (e.g., damage-
associated ATP release), lead to disturbed transmembrane ion fluxes
and loss of essential metabolites. Cx43 HC opening might therefore
promote deleterious results, which has been demonstrated in several
pathological conditions, such as ischemia, Alzheimer’s disease and
inflammation (Abudara et al., 2015; De Bock et al., 2014; Giaume et al.,
2013; Montero & Orellana, 2015; Vinken, 2015; Wei et al., 2014).
While in vivo glutamate release linked to Cx43 HC opening has already
been demonstrated in a hypoxia/ischemia rat model (Li et al., 2015; use
of Gap26 mimetic peptide), up to now no in vivo reports are available
pinpointing the contribution of Cx43 HCs to D-serine release. Their
potential function as pathological pores as well as their predominant
and high expression by astrocytes in the hippocampus (Chever, Lee,
et al., 2014; Giaume & Theis, 2010; Kang et al., 2008; Mylvaganam
et al., 2010; Ye et al., 2003), a brain region crucially involved in
epilepsy, led us to hypothesize that in vivo Cx43 HC inhibition may be
a novel treatment strategy for epilepsy.
An increasing number of studies point to a role for Cx43 signaling
in epilepsy (for reviews see Carlen, 2012; Jin & Chen, 2011; Mylvaga-
nam, Ramani, Krawczyk, & Carlen, 2014). Nevertheless, due to a lack of
experimental tools, the exact contribution of either Cx43 HC or Cx43
GJC inhibition in epilepsy remains to be elucidated. Indeed, the use of
Cx knock-out animals or non-selective inhibitors have led to contradic-
tory results, resulting in either proconvulsant or anticonvulsant effects
(Carlen, 2012). In knock-out mice, both HCs and GJCs are deleted, as
these channels are built up by the same proteins, and compensatory
mechanisms are possible (Nielsen et al., 2017; Suadicani, De Pina-
Benabou, Urban-Maldonado, Spray, & Scemes, 2003; Theis et al.,
2003). Previously used inhibitors have poor selectivity for different Cx
species, affect both HCs and GJCs, and have significant effects on
other targets (e.g., pannexin HCs and voltage-gated Ca21 channels;
Carlen, 2012; Herve & Sarrouilhe, 2005; Jin & Chen, 2011; Nielsen
et al., 2017; Willebrords, Maes, Crespo Yanguas, & Vinken, 2017).
To explore the role of Cx43 HCs in seizures, we used TAT-Gap19
to block HC function without reducing GJCC via Cx43-based channels
(Abudara et al., 2014). Gap19 is a synthetic nonapeptide derived from
the intracellular L2 domain of Cx43 and specifically disturbs intramolec-
ular interactions between the cytoplasmic loop (CL) and the carboxy-
terminal tail (CT) (Wang et al., 2013a; Figure1). These loop-tail interac-
tions distinctly affect Cx43 HCs and GJCs, with GJCs being closed by
these interactions, while HCs need these interactions to become avail-
able to open with electrical or chemical triggers (Wang et al., 2013b,
Iyyathurai et al., 2013; reviewed in Leybaert et al., 2017). Gap19 has
been demonstrated to inhibit Cx43 HCs while having no effect on
Cx40 HCs, pannexin1 channels (Wang et al., 2013a) and Cx43 GJs
(Abudara et al., 2014). The peptide targets and interacts with a
sequence on the intracellular C-terminal domain, which is indeed very
different between distinct Cxs, while the extracellular regions (e.g., tar-
geted by Gap26, Gap27) are very well conserved (Wang et al., 2013a).
As a result, Gap19 has intrinsically less chance of interacting with Cxs
other than Cx43.
In the present study, we first performed in vitro mechanistic
experiments in hippocampal slices demonstrating that the chemocon-
vulsant pilocarpine induces astroglial Cx43 HC opening which was
blocked by the Cx43 HC inhibitor TAT-Gap19. Next, we carried out in
vivo experiments to assess the effect of TAT-Gap19 on pilocarpine-
induced limbic seizures and gliotransmitter release. Finally, we further
explored the therapeutic potential of Cx43 HC inhibition in an acute
and chronic electrical seizure mouse model of refractory seizures.
2 | MATERIALS AND METHODS
2.1 | Animals
Animals were housed at constant temperature (218C 6 38C)/relative
humidity (55% 6 10%) in a 12/12 hr light/dark cycle with free access
to food and water. All efforts were made to minimize the number of
animals used, their suffering and results are reported in accordance
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with the ARRIVE guidelines (Kilkenny, Browne, Cuthill, Emerson, & Alt-
man, 2010).
Acute brain slices were obtained from 2-month-old GFAP-eGFP
transgenic mice of either sex, generated in the SPF animal facility of
Collège de France. In these mice, astrocytes are labeled by the
enhanced green fluorescent protein (eGFP) under the control of the
human glial fibrillary acidic protein (GFAP) promotor, to be able to visu-
alize astrocytes by direct fluorescence microscopy (Nolte et al., 2001).
Experiments were performed according to the European Community
Council Directives (2010/63/EU).
In vivo experiments were performed on male NMRI mice weighing
20–30 g and male Wistar rats weighing 250–300 g at time of surgery
(Charles River Laboratories, Cha^tillon-sur-Chalaronne, France). Animals
acclimatized at least 1 week to the animal facility and 1 day to the
experimental room before being used in experiments. All procedures
were carried out in accordance with the National Rules on Animal
Experiments and were approved by the Ethical Committee for Animal
Experiments of the Vrije Universiteit Brussel, Belgium.
2.2 | Experimental design
Slices or animals were randomly assigned to an experimental group and
results were obtained as follows: automated software was used for dye
uptake experiments and liquid chromatography analyses. For the focal
pilocarpine mouse model, total seizure duration (depicted on electroen-
cephalographic (ECoG) recordings) was counted blinded to treatment.
For the focal pilocarpine rat model and acute 6 Hz mouse model,
syringes were coded by another experimenter. As experiments cannot
be performed blinded in the 6 Hz corneal kindling model, behavior was
scored by two independent experimenters. Sample size was deter-
mined a priori based on previous experience with the models.
2.3 | Connexin inhibitors and control peptides
Carbenoxolone (CBX; MW 614.72 g/mol, Sigma-Aldrich, Steinheim,
Germany), a glycyrrhetinic acid derivate, was used as a non-selective
Cx channel inhibitor (positive control). TAT-Gap19 (MW 2703 Da),
TAT-Gap19I130A, scrambled TAT-Gap19 and TAT (MW 1560 Da)
were synthesized by Pepnome Inc. (Hong Kong, China, >95% purity)
or Genosphere Biotechnologies (Paris, France, >95% purity; Table 1).
TAT-Gap19 was used as a Cx43 HC inhibitor. Gap19 was coupled to
the transactivator of transcription (TAT)-sequence of the HIV-1 virus
to increase its cell membrane permeability, as the CT target is intracell-
ularly located (Wang et al., 2013a). Three different negative control
peptides were used throughout the experiments. (a) TAT-Gap19I130A,
an I130A-modified Gap19 analogue, was chosen since amino acid I130
is involved in the formation of hydrogen bonds and thereby important
for Gap19 activity. This mutant was demonstrated to have no effects
on Cx43 HCs (Wang et al., 2013a). (b) Additionally, a scrambled version
of TAT-Gap19 (i.e., scrambled TAT-Gap19) was used as a control pep-
tide. (c) To rule out effects due to the cell-penetrating TAT linker, TAT
was also subjected to several models.
Compounds were freshly dissolved in oxygenated artificial cere-
brospinal fluid (aCSF) (for acute brain slice experiments), 0.1 M phos-
phate buffered saline (PBS; Sigma-Aldrich, Steinheim, Germany; for
intracerebroventricular (i.c.v.) administration), saline (0.9% NaCl, Baxter,
Lessines, Belgium; for intraperitoneal (i.p.) administration) or modified
Ringer’s solution (for intrahippocampal administration). Doses and
treatment time intervals were based on literature data (Abudara et al.,
2014; Chever, Lee, et al., 2014; Walrave et al., 2016; Wang et al.,
2013a) or dose-response studies (data not shown).
2.4 | Ethidium bromide uptake experiments in acute
brain slices
GFAP-eGFP mice were sacrificed by cervical dislocation, decapitated
and their brains were dissected and placed in ice-cold slicing medium
containing (in mM) glucose (10.00), sucrose (222.00), NaHCO3 (27.00),
KCl (2.60), NaH2PO4.H2O (1.25), MgSO4.7H2O (7.00), ascorbic acid
(0.10), CaCl2.2H2O (0.50); bubbled with 95% O2/5% CO2 (290–
300 mOsm). Coronal brain hemisphere slices (300 mm) were cut on a
vibroslicer (Microm HM 650 V, Thermo Scientific, Walldorf, Germany)
and transferred to a nylon mesh submerged in oxygenated aCSF. Slices
were incubated 30 min at 328C and 30 min at room temperature (RT).
The aCSF solution contained (in mM) NaCl (125.00), KCl (2.50),
NaH2PO4.H2O (1.25), NaHCO3 (25.00), glucose (25.00), MgCl2 (1.00),
and CaCl2.2H2O (2.00) (300–320 mOsm).
Acute brain slices were incubated with oxygenated aCSF with or
without inhibitor (CBX, TAT-Gap19) or negative control peptide (here
TAT and scrambled TAT-Gap19). Since the lack of effect with 100 mM
TAT-Gap19 (Wang et al., 2013a) in our first slice experiments (n 5 3),
we opted to use 200 mM inhibitor for the remainder of the experiments.
Pilocarpine (15 mM, Sigma-Aldrich, Steinheim, Germany) was added
to the incubation chambers (except for control condition) and slices
were treated for 40 min to trigger HC activity in astrocytes. The test
conditions included: (a) control where slices were only exposed to aCSF
(Ctr), (b) 40 min exposure to pilocarpine alone (P40), and exposure to (c)
CBX, (d) TAT-Gap19, (e) TAT, or (f) scrambled TAT-Gap19 (all 200 mM),
15 min before and during pilocarpine treatment (i.e., CBX 1 P40,
TG19 1 P40, TAT 1 P40, scrTG19 1 P40, respectively). Next, the HC
permeable fluorescent tracer ethidium bromide (EtBr; 4 mM, Sigma-
Aldrich, Steinheim, Germany) was incubated for 10 min at RT as previ-
ously described (Giaume, Orellana, Abudara, & Saez, 2012). Finally, sli-
ces were rinsed for 15 min in aCSF to stop dye uptake and reduce
background labeling. Slices were submerged for 40 min in fixing solution
(4% paraformaldehyde in PBS) and rinsed in PBS before mounting in
Fluoromount-G mounting medium (Southern Biotechnology Associates,
Inc., Birmingham, USA). At least six images covering the interpyramidal
TABLE 1 Overview of the different peptides used in this study
Peptide Amino acid sequence
TAT YGRKKRRQRRR
TAT-Gap19 YGRKKRRQRRR-KQIEIKKFK
TAT-Gap19I130A YGRKKRRQRRR-KQAEIKKFK
Scrambled TAT-Gap19 YGRKKRRQRRR-IEKFKIKQK
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zone of the CA1 to CA3 hippocampus were captured for each experi-
mental condition with a 40X objective using a confocal laser-scanning
microscope (Leica TCS SP5, Leica, Wetzlar, Germany). Stacks of 22 con-
secutive confocal images at 0.49 mm intervals were acquired sequen-
tially with two different laser wavelengths (argon 488 nm for eGFP and
561 nm for EtBr). Images were processed with Image J (Fiji; National
Institutes of Health (NIH) software; Schindelin et al., 2012) with a macro
for automated analysis. All cells that were eGFP-positive were identified
as astrocytes and EtBr fluorescence intensity was then measured within
these eGFP-positive cells. Fluorescence was quantified in arbitrary units
and EtBr uptake intensity was evaluated as the difference between the
fluorescence from astrocytes (at least 20–30 cells per image) and back-
ground fluorescence measured in the same field where no labeled cells
were detected. Averages of all eGFP-positive cells of at least six images
were calculated as the final measurement of dye uptake in that condi-
tion. Finally, the EtBr uptake in each condition was normalized to the
concurrent control condition for graphic representation of the data.
2.5 | Surgery
All animals received 4 mg/kg ketoprofen (Ketofen, Merial, Toulouse,
France) subcutaneously (s.c.) before surgery to prevent post-operative
pain and inflammation.
For the pilocarpine mouse model (intrahippocampal administra-
tion), a microdialysis guide (MAB6.10.IC, Microbiotech/se AB, Stock-
holm, Sweden) was implanted 2 mm above the left hippocampus (from
bregma, mm: anterior–posterior (AP) – 2.70, medial-lateral (ML)13.0;
and – 1.5 below dura mater) under 2.5%–3% isoflurane anesthesia (Iso-
vet, Dechra Veterinary Products, Bladel, The Netherlands). Additionally,
mice were s.c. implanted with a sterilized (Actril Cold Sterilant, Mediva-
tors B.V., Heerlen, The Netherlands) radiotelemetric mouse transmitter
(DSI PhysioTel ETA-F10; Data Sciences International, Tilburg, The
Netherlands) to assess seizure severity. By means of stainless steel
screws, the measuring electrode was positioned above the right hippo-
campus (contralateral site of microdialysis guide) and the reference
electrode above the cerebellum (AP – 1 mm according to lambda). The
guide and electrodes were fixated with dental cement. After transmit-
ter implantation, 4 mg/kg enrofloxacin s.c. (Baytril, Bayer, Diegem, Bel-
gium) was given to prevent bacterial infections.
For the acute 6 Hz seizure mouse model (i.c.v. administration), a
guide cannula (3 mm, 26 GA, Bilaney Consultants, D€usseldorf, Ger-
many) was implanted stereotactically in the left brain ventricle (from
bregma, mm: AP – 0.34, ML11, dorso-ventral (DV) – 2.20). The mice
were single-housed to avoid cannulated mice from chewing on each
other’s cannulas and were allowed to recover for 7 days. A stylus (Bila-
ney Consultants, Düsseldorf, Germany) was placed inside the guide
cannula to preclude clogging.
Wistar rats were anesthetized with a mixture of ketamine:diaz-
epam (start dose 90.5:4.5 mg/kg i.p.; ketamine 1000 Ceva, Ceva Sante
Animale; Valium, Roche, both Brussels, Belgium). A microdialysis guide
(MAB6.14.IC, Microbiotech/se AB, Stockholm, Sweden) was implanted
stereotactically above the left hippocampus (from bregma, mm: AP –
5.6, ML14.6; and 24.6 below dura mater). Two anchor screws were
placed in the skull and dental cement was applied to fixate the guide
cannula to the skull.
After surgery, mice and rats received 1 or 5 ml saline i.p. respec-
tively to prevent dehydration and were placed in front of an infrared
lamp or on a heating mat for 15 min to safely raise core body tempera-
ture. At the end of the experiments, animals were sacrificed with
200 mg/kg sodium pentobarbital (Nembutal, Ceva Sante Animale,
Libourne, France) and accuracy of guide implantation was verified post-
mortem and compared against an anatomic atlas (Paxinos & Franklin,
2004; Paxinos & Watson, 2005).
2.6 | Focal pilocarpine model in mice
After removing the inner guide cannula, an MAB6.10.2 probe (2 mm
membrane, 15 kDa cut-off, Microbiotech/se AB, Stockholm, Sweden)
was inserted and probes were continuously perfused with modified
Ringer’s solution containing (in mM) NaCl (147), KCl (4) and
CaCl2.6H2O (2.3), at a flow rate of 2 ml/min (CMA 400 Syringe Pump,
CMA Microdialysis, Kista, Sweden). The animals recovered overnight in
their microdialysis cage and all experiments in freely-moving mice
started the next day. Each experiment started with modified Ringer’s
solution perfusion for 60 min (baseline conditions). In the pretreatment
protocol, this was followed by a 60 min pretreatment period with vehi-
cle, scrambled TAT-Gap19 or TAT-Gap19. Next, seizures were evoked
by intrahippocampal pilocarpine perfusion (12 mM, 40 min) in the pres-
ence of vehicle, scrambled TAT-Gap19 or TAT-Gap19. Perfusion of
vehicle or peptides lasted until the end of the experiment (for another
100 min) (detailed protocol in Figure 3 upper panel). In a subset of
mice, dialysate samples were collected every 10 min and analyzed for
D-serine levels via an enantioselective high-performance liquid chroma-
tography (HPLC) method described in Section 2.10.
In a second set of experiments, we investigated the possible
attenuation of D-serine levels as a part of the anticonvulsant action of
TAT-Gap19. Therefore, we used a similar microdialysis protocol as
described above, but now administered a high dose of D-serine
(600 mg/kg i.p., Sigma-Aldrich, Steinheim, Germany) 20 min before
TAT-Gap19 perfusion. Next, i.p. injections of 300 mg/kg D-serine were
repeated every hour until the end of the experiment (detailed protocol
in Figure 4b upper panel). This dose of D-serine is similar to the one
used in several studies (Duffy, Labrie, & Roder, 2008; Gomez-Galan
et al., 2013; Seif et al., 2015) and adopted to replenish extracellular D-
serine levels. The dose-regimen rationale was based on the half-life of
D-serine in mice (i.e., t1/2 1 hr; Rais et al., 2012).
Moreover, to investigate whether Cx43 HC inhibition can interrupt
ongoing seizure activity, additional microdialysis experiments were per-
formed in which TAT-Gap19 was administered 20 min after the occur-
rence of pilocarpine-induced seizures (post-onset), lasting until the end
of the experiment (detailed protocol in Supporting Information Figure
S2, upper panel).
ECoG monitoring was used to measure seizure duration in each
mouse. Mice implanted with a radiotelemetric transmitter were placed
in a video-ECoG monitoring unit equipped with a radiotelemetric
receiver (PhysioTel Receiver Model RPC-1; Data Sciences International,
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Tilburg, The Netherlands) coupled to the Notocord-hem Evolution
acquisition software (Notocord, Croissy-sur-Seine, France). During the
microdialysis experiment, the ECoG was sampled with a frequency of
100 Hz and total seizure duration was calculated as the sum of the
duration of all individual seizures by a scientist blinded to treatment.
Calculation of one seizure started from the time of identifiable change
of ECoG activity to the end of ictal ECoG activity and these changes
had to last for minimum 5 s. Two consecutive seizures were counted
as one seizure when they were separated with less than 30 s.
2.7 | Focal pilocarpine model in rats
The in vivo microdialysis pretreatment protocol in freely-moving rats
was similar to the one described above in mice. We however used an
MAB6.14.3 probe (3 mm membrane length, 15 kDa cut-off, Microbio-
tech/se AB, Stockholm, Sweden). The detailed protocol is given in Fig-
ure 5, upper panel.
Since rats show typical seizure-related behavioral changes in this
model, a modified Racine’s scale was used to score seizure severity
with stages (0) normal, non-epileptic behavior, (1) mouth and facial
movements, hyperactivity, excessive grooming, sniffing, scratching, wet
dog shakes, (2) head-nodding, staring, tremor, (3) forelimb clonus/
extension, (4) rearing, salivating, tonic-clonic activity and (5) falling
(Racine, 1972). This scale was previously validated by our research
group by ECoG monitoring (Meurs, Clinckers, Ebinger, Michotte, &
Smolders, 2008). For every 20 min, the highest seizure severity score
(SSS) was assigned, starting from pilocarpine perfusion until the end of
the experiment (in total 140 min or seven collection periods). The total
seizure severity score (TSSS) for each animal is calculated as the sum of
these seven SSSs and was used as a measure of seizure severity.
2.8 | Acute 6 Hz mouse model of refractory seizures
Limbic psychomotor seizures were evoked via corneal stimulation (6 Hz,
0.2 ms rectangular pulse width, 3 s duration) using an ECT Unit 57800
stimulator (Ugo Basile, Varese, Italy). All experiments were performed at
a current intensity of 49 mA, found to be optimal in a current-response
study (Walrave et al., 2015). A drop of 0.5% xylocaine (AstraZeneca,
Brussels, Belgium) in saline was applied to the eyes to induce local anes-
thesia and ensure good conductivity. After stimulation, the animals were
gently placed in an open plastic cage (35 3 55 cm) to observe the pres-
ence or absence of seizure activity, which is characterized by stun, fore-
limb clonus and/or elevated Straub-tail. For each animal, the total seizure
duration was manually recorded by a scientist blinded for treatment.
For the i.c.v. experiments, in which compounds are directly deliv-
ered into the ventricle, the stylus was removed from the guide cannula
on the day of the experiment and a 33 GA injection cannula (Bilaney
Consultants, D€usseldorf, Germany) was inserted through the guide can-
nula, extending 1 mm beyond its tip in the ventricle. TAT-Gap19, its
inactive mutant peptide (TAT-Gap19I130A), TAT (all 1 mM solutions)
or vehicle (PBS) was infused in the ventricle via the injection cannula
for 2 min at a flow rate of 0.5 ml/min (total 1 ml; CMA 400 Syringe
Pump, CMA Microdialysis, Kista, Sweden), 60 min prior to the corneal
stimulation. Following drug infusion, injection cannulas were left in
place for 1 min to allow drug diffusion away from the cannula tip. Thus,
mice received either 2.7 mg/ml (1 nmol/ml) TAT-Gap19, 2.7 mg/ml
(1 nmol/ml) TAT-Gap19I130A, 1.56 mg/ml (1 nmol/ml) TAT or 1 ml PBS i.
c.v. We previously demonstrated TAT-Gap19 diffusion from ventricle
to hippocampus (Walrave et al., 2016).
For the i.p. experiments, 25 mg/kg TAT-Gap19, its inactive
scrambled version (25 mg/kg scrambled TAT-Gap19) or vehicle (0.9%
NaCl) was administered 60 min prior to the corneal stimulation.
2.9 | Chronic 6 Hz corneal kindling mouse model
Initially, we explored different current intensities, applied once, to find a
subconvulsive current intensity in male NMRI mice (i.e., 19 mA, data not
shown). These animals were not included in the actual kindling experiment.
Mice were stimulated twice daily (between 8–10 hr and 14–16 hr,
Monday to Friday) at a fixed, initially subconvulsive threshold current
(19 mA, 0.2 ms monopolar pulses, 6 Hz, 3 s; ECT Unit 57800, Ugo
Basile, Varese, Italy) via corneal electrodes until reaching the fully
kindled state (i.e., displaying 10 consecutive generalized seizures; acqui-
sition phase). Prior to each stimulation, 0.5% xylocaine (AstraZeneca,
Brussels, Belgium) was applied to the eyes. After stimulation, mice
were immediately placed in a plastic cage and observed until the end
of the seizure. A modified Racine’s scale was used to score kindling-
induced behavioral changes with stages (0) normal, non-epileptic
behavior, (1) facial twitches and chewing, (2) head-nodding, (2,5) unilat-
eral forelimb clonus, (3) bilateral forelimb clonus, (4) rearing with fore-
limb clonus and (5) generalized clonus with rearing and falling (Coppens
et al., 2016). At the beginning, mice develop focal seizures (Stages 1
and 2), which evolve to generalized seizures (Stages 3–5) due to
repeated subconvulsive stimulations. Mice that reached the fully
kindled state were only stimulated twice a week (Monday/Thursday or
Tuesday/Friday; maintenance phase). After maximum 5 weeks of stim-
ulation, all non-kindled animals were discarded.
To test the anticonvulsant effect of TAT-Gap19 in fully-kindled
mice, animals were stimulated on Monday morning without any inter-
vention (STIM 1), on Monday afternoon with vehicle (0.9% NaCl i.p.,
60 min prior to stimulation; STIM 2), on Tuesday morning without any
intervention (STIM 3) and on Tuesday afternoon with TAT-Gap19 (25
or 50 mg/kg i.p., 60 min before stimulation; STIM 4).
Fully-kindled animals that exhibited a generalized seizure (Stages
3–5) both after vehicle (STIM 2) and morning stimulation (STIM 3)
were included in the experiments. All fully-kindled animals used in the
experiments met these criteria (100% inclusion rate). Seizure severity
was assessed by two independent experimenters and scores following
vehicle and TAT-Gap19 administration were compared.
2.10 | Enantioselective liquid chromatography method
for D-serine analysis
D-serine levels were measured in the dialysates which were obtained in
the focal pilocarpine mouse model (pretreatment protocol) using an
HPLC system (Shimadzu, Duisberg, Germany) coupled with a spectro-
fluorimetric detector (Shimadzu), as described previously (Gomez-Galan
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et al., 2013). Briefly, D-serine was separated on a Capcell Pak C18 type
MH column (Shiseido, Tokyo, Japan) with 2 mm diameter and 250 mm
length. D-serine was eluted with gradient elution, by using mobile phase
A (0.025 M Na2HPO4.12H2O, pH 9) and mobile phase B (methanol:
ultrapure water, 60:40 V/V; 0.17 ml/min). Derivatisation was per-
formed at 48C by adding 9 ll of the derivatisation mixture, containing
ortho-phtalaldehyde and N-isobutyryl-L-cysteine (both Sigma-Aldrich,
Steinheim, Germany) to 9 ml sample. Chromatograms were recorded
with 340 nm excitation and 450 nm emission wavelengths and intre-
gration was obtained with the Chromeleon software (ThermoScientific,
Waltham, MA, USA). Standards (0, 0.25, 0.50, 0.75, and 1 mM) were
made by spiking modified Ringer’s solution with standard D-serine
(Sigma-Aldrich, Steinheim, Germany).
2.11 | Data analyses and statistics
Statistical analyses were performed using GraphPad Prism 6.01 (Graph-
Pad Software, Inc. La Jolla, CA) with a set at 0.05. Data are expressed
as means 6 SEM. D’Agostino-Pearson omnibus normality test was
used to verify data distribution. Two-sided t test (normal data) or two-
sided Mann-Whitney test (non-normal data) was used to denote signifi-
cant differences between two experimental groups. To compare three
different groups, one-way ANOVA followed by Tukey’s multiple com-
parisons post hoc test (normal data) or Kruskal-Wallis followed by a
Dunn’s multiple comparisons post hoc test (non-normal data) was used.
To compare paired measurements (of non-normal or categorical data),
two-sided Wilcoxon matched-pairs signed-rank test (WMS; two
groups) or Friedman test (four groups) was used. When more than one
variable was assessed, two-way ANOVA followed by Tukey’s post hoc
test was used. Fisher’s exact test was used to compare number of gen-
eralized seizures in 6 Hz kindling experiment. The appropriate statistical
test is denoted in the results section and figure legends.
3 | RESULTS
3.1 | Pilocarpine induces Cx43 HC opening in
astrocytes studied in acute brain slices
The chemoconvulsant pilocarpine is widely used ex vivo to induce epi-
leptiform activity in hippocampal slices (Curia, Longo, Biagini, Jones, &
Avoli, 2008; Marchi et al., 2007; Nagao, Alonso, & Avoli, 1996; Portelli
et al., 2012). We here investigated the effect of pilocarpine on astro-
cytic HC opening (measured via EtBr dye uptake) in the interpyramidal
zone of the CA1/CA2/CA3 region of acute hippocampal slices from
GFAP-eGFP mice. Pilocarpine (15 mM, 40 min) induced astrocytic HC
opening, as indicated by an on average twofold increase in EtBr signal
in GFAP-positive astrocytes (P40: 211.50% 6 20.10% of control,
n 5 14, two-sided WMS, p 5 .0001 compared with Ctr; Figure 2a).
This effect was suppressed by CBX (200 mM), a non-selective
blocker that inhibits both Cx and pannexin channels at the concentra-
tion applied, suggesting that EtBr uptake occurred through Cx HCs or
pannexin channels (CBX1P40: 77.13% 6 22.65% of control, n 5 7,
two-sided WMS, p 5 .0156 compared with P40).
The pilocarpine-induced EtBr uptake in astrocytes was also signifi-
cantly decreased by 200 mM TAT-Gap19 (TG19 1 P40:
140.20% 6 12.06% of control, n 5 8, two-sided WMS, p 5 .0078
compared with P40). As TAT-Gap19 is a more specific Cx43 HC
blocker, this suggests that substantial astrocytic dye uptake occurred
through HCs composed of Cx43.
There were no significant differences between pilocarpine treated
slices and slices that were pre-treated with each of the TAT-Gap19 con-
trol peptides, namely the TAT sequence alone (TAT 1 P40:
200.08% 6 18.96% of control, n 5 7, p 5 .4375 compared with P40)
and the scrambled version of TAT-Gap19 (scrTG19 1 P40:
207.10% 6 44.84% of control, n 5 7, p 5 .5781 compared with P40,
both two-sided WMS). Importantly, TAT-Gap19 significantly decreased
EtBr uptake compared with the control peptides (TAT 1 P40 and
scrTG19 1 P40 both p 5 .0313 compared with TG191 P40, both two-
sidedWMS). By contrast, the CBX and TAT-Gap19 condition did not sig-
nificantly differ from the concurrent control condition (CBX 1 P40
p5 .2969 and TG191 P40 p5 .078 compared with Ctr, both two-sided
WMS). Representative images of EtBr uptake are depicted in Figure 2b.
3.2 | Intrahippocampal TAT-Gap19 attenuates
pilocarpine-induced seizures and accompanying
increases in extracellular D-serine levels in mice
Subsequently, TAT-Gap19 was tested in vivo in the focal pilocarpine
model, in which pilocarpine is perfused in the hippocampus of rodents
to evoke limbic seizures. In the pretreatment protocol in mice, TAT-
Gap19 is administered 60 min prior to seizure induction. No
FIGURE 1 Position of the Gap19 sequence in the cytoplasmic
loop (CL) domain of connexin43 (Cx43). Gap19 inhibits Cx43
hemichannel opening by interacting with the last nine amino acids
of the carboxy-terminal tail (CT; Illustration generated with the
Protter tool; Omasits, Ahrens, M€uller, & Wollscheid, 2014) [Color
figure can be viewed at wileyonlinelibrary.com]
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anticonvulsant effects were observed with 12.5 mM TAT-Gap19
(2,824 6 968 s, n 5 8), as total seizure duration did not significantly
differ from control mice receiving vehicle (modified Ringer’s solution,
4,520 6 579 s, n 5 14, Kruskal-Wallis test (H 5 2.439, p 5 .2953) fol-
lowed by Dunn’s post hoc test, p 5 .4197) or 12.5 mM of the control
peptide scrambled TAT-Gap19 (4,453 6 1,211 s, n 5 7, Dunn’s test
post hoc test, p 5 .6542; Figure 3a).
Perfusion of 25 mM TAT-Gap19 however led to a clear significant
decrease of total seizure duration (2,113 6 607 s, n 5 12) compared
with mice receiving 25 mM scrambled TAT-Gap19 (4,120 6 569 s,
n5 14, two-sided t test, t5 2.411, p5 .0239; Figure 3b), although with-
out changing the latency to first seizure (1,888 6 538 s for scrambled
peptide and 2,190 6 693 s for TAT-Gap19 peptide; two-sided Mann-
Whitney test, U 5 81.00, p 5 .8885, Supporting Information Figure S1).
Noteworthy, total seizure duration in vehicle and scrambled TAT-Gap19
treated animals was similar. Representative in vivo ECoG recordings of a
25 mM scrambled TAT-Gap19 and 25 mM TAT-Gap19 treated mouse are
depicted in Figure 3c,d. These results indicate that pretreatment with
TAT-Gap19 is able to attenuate pilocarpine-induced seizures.
On the contrary, when TAT-Gap19 was administered 20 min after
seizure onset, the total seizure duration from mice receiving 50 mM
TAT-Gap19 (3,423 6 934 s, n 5 6) did not significantly differ from the
control mice receiving vehicle (3,743 6 813 s, n 5 6, two-sided Mann-
Whitney test, U 5 14.00, p 5 .5714), implicating that Cx43 HC
FIGURE 2 Pilocarpine treatment increases ethidium bromide (EtBr) uptake through astrocytic hemichannels (HCs) in acute hippocampal
slices. (a) Averaged data normalized to control (Ctr) (dashed line) of EtBr uptake in GFAP-eGFP positive hippocampal astrocytes treated for
40 min with pilocarpine (15 mM) alone (P40) and in presence of the non-selective Cx/pannexin channel inhibitor carbenoxolone
(CBX 1 P40), the Cx43 HC inhibitor TAT-Gap19 (TG19 1 P40) and its two negative control peptides TAT (TAT 1 P40) and scrambled TAT-
Gap19 (scrTG19 1 P40), all applied at 200 mM, 15 min before pilocarpine treatment and during dye uptake measurement. (b) Fluorescence
representative images of acute hippocampal slices derived from GFAP-eGFP transgenic mice show GFAP-eGFP astrocytes (green) and EtBr
uptake (red). Images of hippocampal astrocytes were taken from the CA1–CA3 interpyramidal zone. Statistics: (a) Two-sided Wilcoxon
matched-pairs signed-rank test with ***p < .001, *p < .05: significant increase compared with Ctr; $$p < .01, $p < .05: significant decrease
compared with P40, #p < .05 significant difference between TAT-Gap19 and control peptides
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inhibition was unable to interrupt full-blown seizure activity (Support-
ing Information Figure S2).
To evaluate whether Cx43 HCs contribute to gliotransmitter
release in vivo during seizures, D-serine was analyzed in the microdialy-
sis samples of a subset of mice receiving 25 mM TAT-Gap19 and
25 mM scrambled TAT-Gap19 (pretreatment protocol).
Since baseline D-serine dialysate levels were not different between
scrambled TAT-Gap19 (0.326 0.06 mM, n5 6) and TAT-Gap19 treated
animals (0.34 6 0.04 mM, n 5 9; two-sided Mann-Whitney test,
U 5 25.00, p 5 .8212, data not shown), D-serine levels are expressed as
a percentage of the baseline levels (Figure 4a). The average basal
dialysate level was determined from the first six samples (60 min) prior
to peptide administration. Next, data were transformed to the percent
change in dialysate level compared with average baseline. A two-way
ANOVA revealed an overall treatment effect meaning that D-serine lev-
els were higher in the scrambled TAT-Gap19 group (116.7 6 2.74%)
compared with the TAT-Gap19 group (97.99 6 1.91%; Column Factor,
F(1,338) 5 19.69, p < .0001). This means that extracellular D-serine lev-
els are increased during pilocarpine-induced seizures and that Cx43 HC
inhibition is able to prevent this increase. We therefore suggest that
Cx43 HCs, in a direct or indirect matter, facilitate D-serine release in
vivo during seizures.
FIGURE 3 (a and b) Experimental microdialysis pretreatment protocol (upper panel) and dose-response experiments of TAT-Gap19 against
pilocarpine-induced seizures in mice. Results are expressed as mean total seizure duration 6 SEM. (a) While 12.5 mM TAT-Gap19 (TG19,
n 5 7) exerted no anticonvulsant effects compared with vehicle (modified Ringer’s solution, n 5 14) or scrambled control peptide (12.5 mM
scrTG19, n 5 7), (b) 25 mM TG19 (n 5 12) significantly decreased total seizure duration compared with scrambled control peptide (25 mM
scrTG19, n 5 12). (c and d) Representative ECoG recordings of (c) a control experiment with 25 mM scrambled TAT-Gap19 (total seizure
duration: 4,908 s) and (d) an experiment with 25 mM TAT-Gap19 (total seizure duration: 1,890 s; movement artefacts were removed). Statis-
tics: (a) Kruskal-Wallis with Dunn’s multiple comparisons post hoc test and (b) Two-sided t test with *p < .05
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3.3 | The anticonvulsant action of TAT-Gap19 in the
focal pilocarpine mouse model is abolished by
exogenous D-serine
We thus hypothesize that the attenuation of D-serine release might be
involved in the anticonvulsant effect of TAT-Gap19. To test this
hypothesis, additional microdialysis experiments were performed in
which D-serine was co-administered with TAT-Gap19. Figure 4b shows
the effect of D-serine co-administration on pilocarpine-induced seizures
in a vehicle control group and a test group receiving 25 mM TAT-
Gap19 (both n 5 4). The co-administration of D-serine completely abol-
ished the anticonvulsant effect of 25 mM TAT-Gap19 (total seizure
duration vehicle: 4,726 6 834 s vs. TAT-Gap19: 5,606 6 1,089 s, two-
sided Mann-Whitney test, U 5 5.00, p 5 .4857). Noteworthy, there
were no seizures detectable on the ECoGs when D-serine was adminis-
tered alone without pilocarpine (total seizure duration 0 6 0 s, n 5 4).
Respresentative ECoG recordings are depicted in Figure 4c–e.
3.4 | Intrahippocampal TAT-Gap19 attenuates
pilocarpine-induced seizures in rats
We conducted the focal pilocarpine model in a different species (i.e.,
rats) to validate the anticonvulsant effect of TAT-Gap19 within this
chemically-induced seizure model (pretreatment protocol). Following
12 mM pilocarpine perfusion, control rats showed typical seizure-
related behavioral changes. An initial dose-response study was per-
formed with 1 mM (n 5 2), 12.5 mM (n 5 2) and 200 mM TAT-Gap19
(n 5 2). Since 12.5 and 200 mM TAT-Gap19 showed anticonvulsant
effects (data not shown), we pursued the experiments with the lowest
anticonvulsant dose of 12.5 mM TAT-Gap19. The mean TSSS 6 SEM
for the vehicle group was 17.206 3.07 (n 5 5), while the TSSS was sig-
nificantly attenuated by perfusion of 12.5 mM TAT-Gap19 (3.006 0.55,
n5 5; two-sided Mann-Whitney test, U5 0.00, p5 .0079; Figure 5).
3.5 | TAT-Gap19 exerts anticonvulsant effects in the
acute 6 Hz mouse model of refractory seizures after
intracerebral and systemic administration
To exclude that the anticonvulsant effects of TAT-Gap19 against
pilocarpine-induced seizures are model-dependent, we next continued
with compound testing in electrical models for seizures and epilepsy.
Considering the need to test candidate drugs in models of
pharmacoresistant seizures, we investigated whether TAT-Gap19
shows effects in the acute 6 Hz mouse model of electrically-induced
refractory seizures (Barton, Klein, Wolf, & White, 2001; Walrave et al.,
2015). Noteworthy, this model was recently added to the Epilepsy
Therapy Screening Program (ETSP) of the National Institute of Neuro-
logical Disorders and Stroke (NINDS; Barker-Haliski et al., 2017).
Although TAT-Gap19 can be readily detected in brain tissue of
mice following its peripheral administration (Abudara et al., 2014), we
first investigated the local effect of TAT-Gap19 on 6 Hz-evoked seiz-
ures. A one-way ANOVA (F 5 7.360, p 5 .0006) followed by Tukey’s
multiple comparisons post hoc test revealed that i.c.v. administered
TAT-Gap19 significantly attenuated total seizure duration compared
with vehicle i.c.v. (TAT-Gap19: 14 6 1 s, n 5 8 vs. PBS: 33 6 5 s,
n 5 10, p 5 .0048) and control peptides: 1 nmol TAT i.c.v. (38 6 3 s,
n 5 8, p 5 .0005) or 1 nmol TAT-Gap19I130A i.c.v. (28 6 3 s, n 5 12,
p 5 .0385). None of the control peptides exerted anticonvulsant
effects (TAT vs. PBS p 5 .7271, TAT-Gap19I130A vs. PBS p 5 .7323;
Figure 6a).
FIGURE 4 D-serine (D-Ser) involvement in the acute pilocarpine mouse model (pretreatment protocol). (a) Relative change in D-Ser
concentration compared with baseline levels during peptide and pilocarpine administration. Results are expressed as percentage of mean
basal release (%D-Ser) 6 SEM. The solid circles denote D-Ser levels in microdialysates of 25 mM scrambled TAT-Gap19 (scrTG19) treated ani-
mals (n 5 6), while D-Ser levels of 25 mM TAT-Gap19 (TG19) treated animals (n 5 9) are shown in open squares. (b) Experimental microdial-
ysis pretreatment protocol (upper panel) and effect of co-administration of D-Ser together with 25 mM TAT-Gap19 against pilocarpine-
induced seizures in mice. Results are expressed as mean total seizure duration 6 SEM. Exogenous D-Ser abolished the anticonvulsant effects
of TAT-Gap19, as no differences were found between vehicle (modified Ringer’s solution, n 5 4) and TAT-Gap19 (TG19, n 5 4) treated ani-
mals. (c–e) Representative ECoG recordings of (c) an experiment with D-Ser alone (total seizure duration: 0 s), (d) a control experiment with
vehicle and D-Ser co-administration (total seizure duration: 5,865 s) and (e) an experiment with 25 mM TAT-Gap19 and D-Ser co-
administration (total seizure duration: 5,488 s; movement and i.p. injection artefacts were removed). Statistics: (a) Two-way ANOVA with
overall treatment effect ***p < .001, (b) Two-sided Mann-Whitney test
FIGURE 5 Experimental microdialysis pretreatment protocol
(upper panel) and anticonvulsant effect of TAT-Gap19 against
pilocarpine-induced seizures in rats. Results are expressed as mean
total seizure severity score (TSSS) 6 SEM. The perfusion of
12.5 mM TAT-Gap19 (TG19, n 5 5) significantly decreased TSSS
compared with vehicle (modified Ringer’s solution, n 5 5). Statis-
tics: Two-sided Mann-Whitney test with **p < .01
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Since systemic administration is a more relevant delivery route, the
effect of i.p. injected TAT-Gap19 on 6 Hz-evoked refractory seizures
was examined. A Kruskal-Wallis test (H 5 9.212, p 5 .01) followed by
Dunn’s multiple comparisons post-hoc test shows that 25 mg/kg TAT-
Gap19 i.p. (23 6 3 s, n 5 14) significantly attenuated total seizure
duration compared with vehicle (0.9% NaCl i.p., 39 6 6 s, n 5 14,
p 5 .0356) and control peptide (25 mg/kg scrambled TAT-Gap19 i.p.,
40 6 6 s, n 5 6, p 5 .0335). Total seizure duration was not altered in
the scrambled TAT-Gap19 treated group compared with vehicle
(p > .9999; Figure 6b).
Decreasing the TAT-Gap19 dose to 15 mg/kg i.p. (25 6 6 s, n 5 7)
however failed to significantly decrease seizure duration compared
with vehicle (0.9% NaCl i.p., 44 6 8 s, n 5 8, two-sided Mann-Whitney
test, U 5 12.00, p 5 .0718, data not shown).
3.6 | TAT-Gap19 decreases seizure severity in the
6 Hz corneal kindling mouse model
Next, TAT-Gap19 was evaluated in the chronic 6 Hz corneal kindling
model, which is considered as a model of treatment-resistant epilepsy
since partial seizures persist despite treatment with high doses of ASDs
(Leclercq, Matagne, & Kaminski, 2014).
Figure 7a illustrates kindling acquisition and demonstrates that
within 4–5 weeks, mice reached the fully kindled state (i.e., exhibiting
10 consecutive generalized seizures). There was a clear progression in
SSS from 1.10 6 0.36 on the first day, to 4.10 6 0.22 after 5 weeks of
stimulations.
Fully kindled mice (n 5 16) were used to investigate the possible
anticonvulsant role of Cx43 HC inhibition in epileptic animals. The
mean kindling scores of the animals (i.e., the mean SSS starting from
being fully kindled until start of drug testing) did not differ from the
scores obtained from the two morning stimulations (STIM 1 and STIM
3), nor from the vehicle score (STIM 2; for details see Section 2.9;
Friedman test, F 5 3.286, p 5 .3496 for 25 mg/kg TAT-Gap19 experi-
ment and F 5 2.222, p 5 .5276 for 50 mg/kg TAT-Gap19 experiment,
Supporting Information Figure S3).
First, we tested 25 mg/kg TAT-Gap19 i.p. (n 5 8), which is an anti-
convulsant dose in the acute 6 Hz mouse model of refractory seizures.
No statistical differences were observed between 25 mg/kg TAT-
Gap19 SSS (3.63 6 0.18) and vehicle SSS (4.25 6 0.25, two-sided
WMS, p 5 .1250) (Figure 7b).
A higher dose of TAT-Gap19 (50 mg/kg i.p., n 5 16) was examined
in the other fully kindled animals (n 5 8) and in the previously 25 mg/
kg TAT-Gap19 treated animals (n 5 8), following an adequate wash-
out period of 1 week. During this wash-out period, mice were stimu-
lated twice daily for 2 days per week to maintain the kindled state and
no change was seen on the seizure severity. At this dose, the TAT-
Gap19 SSS (2.62 6 0.38) was significantly lower than vehicle SSS
(3.87 6 0.20, two-sided WMS, p 5 .0129; Figure 7c). Generalized seiz-
ures (Stages 3–5) occurred in all vehicle treated animals, while only half
of the animals experienced a generalized seizure following 50 mg/kg
TAT-Gap19, which was significantly different from each other (two-
sided Fisher’s exact test, p 5 .0024, Figure 7d).
4 | DISCUSSION
We here tested whether Cx43 HC inhibition with TAT-Gap19 could
influence seizure activity in in vivo rodent models. Various models were
applied to that purpose, including focal microdialysis-delivered pilocar-
pine model in mice (scored by seizure duration, D-serine measurements)
and rats (scored by TSSS), acute 6 Hz corneal stimulation (scored by
seizure duration) and chronic 6 Hz corneal kindling (scored by SSS) in
mice. In all models, pretreatment with TAT-Gap19 significantly
FIGURE 6 Effect of connexin43 hemichannel (Cx43 HC) inhibition in the acute 6 Hz mouse model of refractory seizures. Results are
expressed as mean total seizure duration 6 SEM. (a) Locally administered TAT-Gap19 (TG19, 2.7 mg/ml i.c.v., n 5 8) significantly decreased
total seizure duration compared with vehicle i.c.v. (PBS, n 5 10), 1.56 mg/ml TAT i.c.v. (n 5 8) or 2.7 mg/ml TAT-Gap19I130A i.c.v.
(TG19I130A, n 5 12). (b) Systemically administered TAT-Gap19 (TG19, 25 mg/kg i.p., n 5 14) significantly decreased the total seizure dura-
tion compared with vehicle (0.9% NaCl, n 5 14) or scrambled TAT-Gap19 (scrTG19, 25 mg/kg i.p., n 5 6). Statistics: (a) One-way ANOVA
with Tukey’s multiple comparisons post hoc test, with **p < .01 compared with PBS, $$$p < .001 compared with TAT and #p < .05 com-
pared with TG19I130A, (b) Kruskal-Wallis with Dunn’s multiple comparisons post hoc test with *p < .05 compared with 0.9% NaCl and
$p < .05 compared with scrTG19
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decreased seizure scores or seizure duration. Mechanistically, pilocar-
pine acted as a trigger of HC opening (based on dye uptake assays) in
acute hippocampal brain slices, which was also inhibited by TAT-
Gap19. Moreover, in vivo microdialysis-delivered pilocarpine increased
D-serine levels in the extracellular fluid, which was suppressed by TAT-
Gap19. Taken overall, these results indicate that Cx43 HC inhibition
impacts seizure activity and that Cx43 HC opening promotes seizure
activity. Below we discuss these findings in more detail.
The chemoconvulsant pilocarpine induced EtBr uptake in astro-
cytes that was approximately twice as large compared with control
conditions. EtBr is a fluorescent tracer that passes from the extracellu-
lar environment to nuclei of cells through either disrupted plasma
membranes or membrane channels that allow EtBr to pass through,
such as Cx HCs. The uptake is proportional to the number of active
(open) HCs (Johnson et al., 2016). We found that both CBX and
TAT-Gap19 significantly decreased pilocarpine-induced EtBr uptake in
GFAP-positive astrocytes. CBX has a larger spectrum of effects, which
includes inhibition of Cx-based GJCs and HCs (e.g., astrocytic Cx30
(Hansen et al., 2014; Pannasch et al., 2014) and neuronal Cx36 (Allison
et al., 2011) as well as pannexin-based channels (Bruzzone, Barbe,
Jakob, & Monyer, 2005). Moreover, CBX has several other well-known
off-target effects, including the inhibition of voltage-gated Ca21 cur-
rents and synaptic transmission, as well as effects on gamma-
aminobutyric acid (GABA) receptors that all largely affect electrical
excitability (Connors 2012; Vessey et al., 2004). None of the control
peptides affected EtBr uptake in pilocarpine treated slices, so effects of
TAT-Gap19 resulted from Cx43 HC inhibition as this peptide was dem-
onstrated not to affect pannexin1 channels (Wang et al., 2013ba). Of
note, we used GFAP-eGFP expressing transgenic mice as a tool to visu-
alize astrocytes. In these mice, not all astrocytes are GFAP-positive and
we also observed EtBr uptake in GFAP-negative cells, which may rep-
resent neurons, GFAP-negative astrocytes (Houades et al., 2006) or
microglial cells as reported by others (Abudara et al., 2014). As pilocar-
pine acts on neurons, it is conceivable that most of these cells are neu-
rons, especially since TAT-Gap19 did not diminish the EtBr uptake and
adult neurons do not express Cx43 (Theis et al., 2003). Here, we only
quantified EtBr uptake in GFAP-positive cells and uptake was signifi-
cantly inhibited by TAT-Gap19, indicating involvement of astroglial
Cx43 HCs. The pilocarpine-induced Cx43 HC opening can be initiated
via various mechanisms. Pilocarpine induces seizures via its agonistic
FIGURE 7 6 Hz corneal kindling in NMRI mice. (a) Kindling acquisition: mean seizure severity score (SSS) 6 SEM as a function of kindling
stimulations. The mice were considered fully kindled when they displayed at least 10 consecutive generalized seizures (Stages 3–5). (b and
c) Effect of systemically administered TAT-Gap19 (TG19) in the 6 Hz corneal kindling model with (b) effect of 25 mg/kg i.p. (n 5 8) and (c)
effect of 50 mg/kg i.p. (n 5 16) on mean SSS 6 SEM in 6 Hz fully kindled mice. (d) Number of partial and generalized seizures following
vehicle (0.9% NaCl) and 50 mg/kg TG19 i.p treatment in fully kindled mice. Statistics: (b and c) Two-sided Wilcoxon matched-pairs signed-
rank with *p < .05, (d) Two-sided Fisher’s exact test with **p < .01
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effect on neuronal muscarinic M1 receptors and triggers epileptiform
activity in hippocampal slices (Portelli et al., 2012). As such, pilocarpine
strongly promotes electrical excitability, leading to an elevation of [K1]e
and a lowering of [Na1]e and [Ca
21]e (Somjen, 2002). [Ca
21]e can drop
by 0.6–1.15 mM below the normal physiological level as reported in
various epilepsy models (Heinemann, Konnerth, Pumain, & Wadman,
1986). Alterations in this range have been demonstrated to trigger
Cx43 HC opening based on various approaches including pore size
changes, electrophysiology and ATP release (Bruzzone, Guida, Zocchi,
Franco, & De Flora, 2001; Contreras, Saez, Bukauskas, & Bennett,
2003; De Vuyst et al., 2009; Lopez et al., 2016; Thimm, Mechler, Lin,
Rhee, & Lal, 2005; Torres et al., 2012; Ye et al., 2003). M1 receptors
are also expressed on astrocytes (Shelton & McCarthy, 2000) so pilo-
carpine may well be directly targeting astrocytes, thereby signaling
through Gq-proteins that activate phospholipase C, produce inositol tri-
sphosphate and lead to an elevation of the astrocytic [Ca21]i. Recent
evidence indicates that [Ca21]i elevation, besides its modulatory effect
on voltage-triggered HC opening (Wang et al., 2012), may also directly
trigger HC opening in voltage clamped astrocytes at 270 mV (Meunier
et al., 2017; reviewed in Leybaert et al., 2017). Astrocytic [Ca21]i eleva-
tion is a common theme in various epilepsy models (Carmignoto &
Haydon, 2012), making it a likely trigger for epileptic Cx43 HC opening.
Additionally, since pilocarpine was acutely added to the slices, we dem-
onstrated the involvement of astrocytic Cx43 HCs in epileptiform
activity. Opening of astrocytic Cx43 HCs may contribute to the seiz-
urogenic effect of pilocarpine by loss of essential cellular metabolites,
by disturbed transmembrane ion fluxes (De Bock et al., 2014; Giaume
et al., 2013; Montero & Orellana, 2015; Wei et al., 2014), by possibly
leading to cell swelling, by provoking cell death (Decrock et al., 2009)
and/or by releasing (excitatory) gliotransmitters (e.g., glutamate, D-ser-
ine; Orellana et al., 2011; Stehberg et al., 2012). Glutamate is the major
excitatory transmitter in the brain and elevated levels have been
reported in human brain tissues of patients with epilepsy and animal
models of epilepsy. Elevated extracellular glutamate concentrations can
induce N-methyl-D-aspartate (NMDA) receptor-mediated excitotoxic-
ity, which causes neuronal death in epilepsy (Cho, 2013). Besides gluta-
mate, astrocyte-released D-serine acts as an important modulator of
NMDA receptors, thereby promoting their opening, increasing excit-
ability and seizure generation (Clasadonte & Haydon, 2012).
The detailed mechanism underlying astrocytic D-serine release is
still unknown but is in general assumed to be dependent on an increase
in cytosolic Ca21. Astrocytic D-serine release has been reported to
occur via large vesicles and Ca21-dependent exocytosis (Orellana &
Stehberg, 2014). Moreover, a recent study performed in prefrontal cor-
tex slices has shown that in basal conditions, D-serine released by
astrocytes is associated to Cx43 HC activity and is triggered by
increases in [Ca21]i in astrocytes voltage clamped at 270 mV (Meunier
et al., 2017). Up to now, only one in vivo study proposed that astrocytic
Cx43 HCs might release D-serine (Stehberg et al., 2012). In this paper,
Stehberg and colleagues investigated the effect of Cx43 HC inhibition
in a fear-based memory paradigm by using another Cx43 HC inhibitor
called TAT-L2. Of note, the L2 peptide is composed of a sequence
which comprises the Gap19 sequence used in the present study; in
fact, the Gap19 sequence is the most active part within the L2
sequence (Wang et al., 2013a). TAT-L2 impaired fear memory consoli-
dation in the basolateral amygdala and the effect was reversed by
administering a cocktail of gliotransmitters (glutamate, glutamine, lac-
tate, D-serine, glycine, and ATP). The authors therefore postulated that
gliotransmitter release from astrocytes occurred through Cx43 HCs.
Although this study nicely supports the hypothesis that Cx43 HCs con-
tribute to gliotransmission, the exact gliotransmitters released were not
identified nor measured.
We here show for the first time that seizure-enhanced D-serine
dialysate levels can be diminished by TAT-Gap19, suggesting that
astrocytic Cx43 HCs contribute to D-serine release in vivo. This hypoth-
esis was further strengthened as the anticonvulsant action of TAT-
Gap19 was abolished by exogenous D-serine co-administration. D-ser-
ine was administered acutely at a high dose since it causes fairly robust
behavioral effects and significant increases in brain and extracellular D-
serine content, in contrast to inhibitors of D-amino acid oxidase
(DAAO; i.e., the enzyme that degrades D-serine; Smith, Uslaner, & Hut-
son, 2010). Although for future chronic experiments, co-administration
of D-serine with a DAAO inhibitor might reduce the dose of D-serine
and ameliorate side effects associated with high doses of chronic D-ser-
ine administration, such as nephrotoxicity (Chung et al., 2010; Mae-
kawa et al., 2005; Park et al., 2006; Rojas et al., 2016). Our data
suggest that TAT-Gap19 protects against seizures by blocking Cx43
HC-mediated D-serine release. However, the results do not necessarily
mean that D-serine is released directly through Cx43 HCs. Indeed,
open HCs can facilitate Ca21 entry (Bol et al., 2017; Schalper et al.,
2010) that in turn could trigger Ca21-dependent exocytosis or alterna-
tive Ca21-dependent release mechanisms of D-serine indirectly (Hamil-
ton & Attwell, 2010; Martineau, Parpura, & Mothet, 2014).
A possible model-dependent anticonvulsant action of TAT-Gap19
was excluded as TAT-Gap19 retained its effect in an electrically-
induced refractory seizure model and a clinically relevant kindling
model of epilepsy displaying treatment-resistant seizures. Of note, in
2015 the ETSP of NINDS was revised to include preclinical approaches
to model pharmacoresistant seizures. Therefore, the acute 6 Hz electri-
cal stimulation (>44 mA) model and etiologically-relevant chronic dis-
ease models, such as corneal kindling models, are now also
incorporated in the initial “Identification” phase of active compounds
(Barker-Haliski et al., 2017).
The anticonvulsant effects of Cx43 HC inhibition against refractory
seizures we report in this article underscores again the important role
of glia in epilepsy and supports the proceeding of TAT-Gap19 to the
late (“Differentiation”) phase (i.e., phase with more resource-intensive
tests) of the ETSP. Peptidomimetics, neuropeptides and peptidergic tar-
gets are indeed one of the research priorities for the development of
new ASDs with original mechanisms of action. Since peptides often
have low bioavailability (e.g., limited blood–brain barrier penetration;
Dobolyi et al., 2014), TAT-Gap19 was administered in several of our
experiments directly into the brain to demonstrate its anticonvulsive
properties. Regardless, TAT-Gap19 was also CNS-active after sys-
temic administration, indicating favorable blood-brain permeability
properties and the possible application as a drug. Different TAT-
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Gap19 doses were required depending on the used model (i.e., dis-
tinct seizure induction, administration routes, species and seizure
severity assessments).
In conclusion, our study is the first to demonstrate that attenuation
of D-serine dialysate levels is crucial for the anticonvulsant properties
of TAT-Gap19. We propose Cx43 HCs as a novel and druggable target
against seizures, encouraging the further assessment of Cx43 HC
blockers in additional chronic models of epilepsy.
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